1. Pink Sheet
  2. >>Geography
  3. >>Europe

Germany To Tackle Cell And Gene Therapy Funding Barriers

 
• By Francesca Bruce

If approved, new legislation would allow hospitals to apply for funding for ATMPs before marketing authorization.

German Flag and Map
Alamy • Source: Germany rethinks funding routes for cell and gene therapies

A bill making its way through the German legislative system could make it easier for hospitals to secure financing for cell and gene therapies. The Alliance for Regenerative Medicine (ARM) has welcomed the move and says it will “reduce a bureaucratic hurdle that stood in the way of patient access to durable and potentially curative" advanced therapy medicinal products.

The changes will apply to the NUB (new diagnostic and treatment methods) pathway, which finances the costs of new treatments and associated services in hospitals that are not yet covered...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

EU CHMP Opinions And MAA Updates

 
• By Neena Brizmohun

This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the EU, and updates on EU marketing authorization changes recommended by the CHMP.

EMA: ‘Sad To See’ Member States Against Patient Engagement Under EU Pharma Reform

 
• By Eliza Slawther

The European Medicines Agency’s chief medical officer Steffen Thistrup argued that patients are able to understand the “complex regulatory and scientific issues” that the EMA committees discuss when they assess drugs.

EU To Track Decentralized Clinical Trials In CTIS To Support Innovation

 
• By Vibha Sharma

Monitoring the use of decentralized elements in clinical trials is a priority for the European medicines regulatory network.

Why Hympavzi Secured English Funding For Hemophilia B But Not Hemophilia A

 
• By Neena Brizmohun

Pfizer told the Pink Sheet it would work with the health technology assessment institute, NICE, with the hope of making Hympavzi available to patients with hemophilia A via the National Health Service.

More from Geography